Currently out of the existing stock ratings of Tyler Van Buren, 191 are a BUY (83.04%), 36 are a HOLD (15.65%), 3 are a SELL (1.3%).

Tyler Van Buren

Work Performance Price Targets & Ratings Chart

Analyst Tyler Van Buren, currently employed at TD COWEN, carries an average stock price target met ratio of 41.7% that have a potential upside of 24.77% achieved within 168 days.

Tyler Van Buren’s has documented 421 price targets and ratings displayed on 49 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GILD, Gilead Sciences at 22-Apr-2025.

Wall Street Analyst Tyler Van Buren

Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 2/24/2021. The price target of $388.6 was fulfilled within 2 days with a profit of $53.02 (15.8%) receiving and performance score of 79.

Average potential price target upside

of $99.08 (13.05%) on BLUE (BLUEBIRD BIO).
of $89.85 (11.38%) on REGN (REGENERON PHARMACEUTICALS).
of $47.91 (55.2%) on SRPT (SAREPTA THERAPEUTICS).

ADVM Adverum Biotechnologies AGIO Agios Pharm ALLO Allogene Therapeutics APTO Aptose Biosciences BGNE BeiGene Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BLUE Bluebird bio GILD Gilead Sciences GOSS Gossamer Bio HARP Harpoon Therapeutics INCY yte IONS Ionis Pharmaceuticals MRNA Moderna MRTX Mirati Ther NKTR Nektar Therapeutics OTIC Otonomy RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AERI Aerie Pharmaceuticals ARVN Arvinas REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma BBIO BridgeBio Pharma BCRX BioCryst Pharmaceuticals CRNX Crinetics Pharmaceuticals FATE Fate Therapeutics KURA Kura Oncology MGTX MeiraGTx Holdings PLC NRIX Nurix Therapeutics OVID Ovid Therapeutics OYST Oyster Point Pharma PRAX Praxis Precision Medicines PTE Polarityte CRSP Crispr Therapeutics AG NEOS Neos Therapeutics TPTX Turning Point Therapeutics CBAY Cymabay Therapeu CBIO Catalyst Biosciences LPTX Leap Therapeutics ALGS Aligos Therapeutics DCPH Deciphera Pharmaceuticals LLC PSTX Poseida Therapeutics EIDX Eidos Therapeutics IMCR Immunocore Holdings Ltd NLTX Neoleukin Therapeutics TYRA Tyra Biosciences RETA Reata Pharmaceuticals TVTX Travere Therapeutics KROS Keros Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)